findmyKOL
Clinical trialNCT06299761TerminatedPhase 1Interventional

Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications

SponsorBoundless Bio, Inc.Enrollment19Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered as a single agent and in combination with select targeted therapies.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sarcoma Oncology Research Center

    Santa Monica, California, United States

  • Start Midwest

    Grand Rapids, Michigan, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Next Oncology

    Irving, Texas, United States

  • Next Oncology

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BBI-825
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Mar 2024
Primary completion
25 Jun 2025
Completion
25 Jun 2025
Last update posted
8 Jun 2026
Registered enrollment
19
Registry id
NCT06299761
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.